[Advances in the treatment of acromegaly].
Acromegaly is a slow developing chronic debilitating disease caused by a growth hormone (GH)-producing pituitary adenoma. The clinical consequences of acromegaly result both from excess GH secretion and from mass effect of the pituitary tumour. The disease is associated with increased morbidity and mortality compared to normal population. Currently available therapies for acromegaly are transsphenoidal surgery, radiotherapy and medical therapy. The last includes dopamine agonists, slow release formulation of somatostatin analogues and pegvisomant, a GH-receptor antagonist. All these forms of treatment attempt to control the disease by reducing GH secretion from the tumour and inhibiting the growth of adenoma. The decision concerning the choice of therapy should depend on age, the severity of acromegaly and the presence of its complications and should also consider the dangers associated with each treatment. This review paper summarizes the contemporary treatment of acromegaly with special emphasis on their established benefits and risks.
Krysiak
Robert
R
Slaska Akademia Medyczna w Katowicach, Klinika Chorób Wewnetrznych i Farmakologii Klinicznej Katedry Farmakologii. r.krysiak@interia.pl
Okopień
Bogusław
B
Marek
Bogdan
B
D000172:Acromegaly / Q000209:etiology / Q000628:therapy*; D000236:Adenoma / Q000150:complications* / Q000628:therapy*; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000150:complications* / Q000628:therapy*; D019382:Human Growth Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors; D013004:Somatostatin / Q000031:analogs & derivatives
D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D013004:Somatostatin; C406545:pegvisomant